CRISPR Historical Income Statement

CRSP -  USA Stock  

USD 66.96  1.81  2.78%

Historical analysis of CRISPR Therapeutics income statement accounts such as Earning Before Interest and Taxes EBIT of 409.5 M, Gross Profit of 987.2 M or Interest Expense of 10 M can show how well CRISPR Therapeutics AG performed in making a profits. Evaluating CRISPR Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of CRISPR Therapeutics's future profits or losses. Financial Statement Analysis is much more than just reviewing and examining CRISPR Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CRISPR Therapeutics is a good buy for the upcoming year.
Continue to Trending Equities.

CRISPR Therapeutics Net Income

407.48 Million


About CRISPR Income Statement Analysis

CRISPR Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to CRISPR Therapeutics shareholders. The income statement also shows CRISPR investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

CRISPR Therapeutics Income Statement Chart

CRISPR Therapeutics AG Income Statement is one of the three primary financial statements used for reporting CRISPR's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of CRISPR Therapeutics revenue and expense. CRISPR Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
CRISPR Therapeutics Operating Income is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Operating Income of 373.53 Million. As of 26th of June 2022, Revenues is likely to grow to about 987.2 M, while Weighted Average Shares is likely to drop about 62.1 M.

Consolidated Income

The portion of profit or loss for the period; net of income taxes; which is attributable to the consolidated entity; before the deduction of Net Income to Non Controlling Interests.

Earning Before Interest and Taxes EBIT

Earnings Before Interest and Tax is calculated by adding Income Tax Expense and Interest Expense back to Net Income.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in CRISPR Therapeutics financial statement analysis. It represents the amount of money remaining after all of CRISPR Therapeutics AG operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income to Non Controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends Income Statement Impact.


Revenues refers to the total amount of money received by CRISPR Therapeutics for goods sold or services provided during a certain time period. It also includes all of CRISPR Therapeutics sales as well as any other increase in CRISPR Therapeutics AG equity.Revenues are reported on CRISPR Therapeutics income statement and calculated before any expenses are subtracted. Amount of Revenue recognized from goods sold; services rendered; insurance premiums; or other activities that constitute an earning process. Interest income for financial institutions is reported net of interest expense and provision for credit losses.
Most accounts from CRISPR Therapeutics income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into CRISPR Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.CRISPR Therapeutics Operating Income is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Operating Income of 373.53 Million. As of 26th of June 2022, Revenues is likely to grow to about 987.2 M, while Weighted Average Shares is likely to drop about 62.1 M.
 2021 2022 (projected)
Interest Expense9.26 M9.99 M
Gross Profit914.96 M987.2 M

CRISPR Therapeutics income statement Correlations

CRISPR Therapeutics Account Relationship Matchups

CRISPR Therapeutics income statement Accounts

201720182019202020212022 (projected)
Consolidated Income(68.36 M)(164.98 M)66.86 M(348.87 M)377.66 M407.48 M
Earning Before Interest and Taxes EBIT(66.61 M)(164.43 M)67.31 M(348.06 M)379.53 M409.49 M
Earning Before Interest and Taxes USD(66.61 M)(164.43 M)67.31 M(348.06 M)379.53 M409.49 M
Gross Profit41 M3.12 M289.59 M719 K914.96 M987.2 M
Net Income(68.36 M)(164.98 M)66.86 M(348.87 M)377.66 M407.48 M
Net Income Common Stock(68.36 M)(164.98 M)66.86 M(348.87 M)377.66 M407.48 M
Net Income Common Stock USD(68.36 M)(164.98 M)66.86 M(348.87 M)377.66 M407.48 M
Operating Expenses105.64 M162.07 M242.85 M355.15 M541.43 M584.18 M
Operating Income(64.65 M)(158.94 M)46.74 M(354.44 M)373.53 M403.02 M
Revenues41 M3.12 M289.59 M719 K914.96 M987.2 M
Revenues USD41 M3.12 M289.59 M719 K914.96 M987.2 M
Research and Development Expense69.8 M113.77 M179.36 M266.95 M438.63 M473.26 M
Selling General and Administrative Expense35.84 M48.29 M63.49 M88.21 M102.8 M82.2 M
Weighted Average Shares40.06 M47.96 M54.39 M65.95 M75.95 M62.06 M
Weighted Average Shares Diluted40.06 M47.96 M56.93 M65.95 M80.39 M64.9 M
Income Tax Expense1.75 M553 K448 K809 K1.87 M2.02 M

Be your own money manager

Our tools can tell you how much better you can do entering a position in CRISPR Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Analyst Recommendations Now


Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Module

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

CRISPR Therapeutics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
CEO Directory
Screen CEOs from public companies around the world
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Money Managers
Screen money managers from public funds and ETFs managed around the world
Equity Valuation
Check real value of public entities based on technical and fundamental data
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.